Compare ATYR & CLST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATYR | CLST |
|---|---|---|
| Founded | 2005 | 1922 |
| Country | United States | United States |
| Employees | 59 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 66.9M |
| IPO Year | N/A | 2021 |
| Metric | ATYR | CLST |
|---|---|---|
| Price | $0.84 | $16.47 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.20 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 3.5K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | N/A |
| Revenue This Year | $9,628.95 | N/A |
| Revenue Next Year | $156.94 | N/A |
| P/E Ratio | ★ N/A | $38.30 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $10.67 |
| 52 Week High | $7.29 | $16.98 |
| Indicator | ATYR | CLST |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 55.52 |
| Support Level | $0.82 | $15.20 |
| Resistance Level | $0.85 | $16.98 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 7.78 | 25.98 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.